Project Grant R01CA291649
Award Date 8/15/25
Completion Date 7/31/29
Dollars Obligated $2.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, EE. UU.
Similar Awards
- The National Cancer Institute (NCI) awarded a $220,340 Project Grant (CFDA 93.398 - Cancer Research Manpower) to Baylor College of Medicine, effective July 31, 2024 through March 31, 2025. The grant supports a research project titled "Targeting the RNA Helicase DDX6 in Acute Myeloid Leukemia". The project aims to conduct innovative research on acute myeloid leukemia (AML), an aggressive blood cancer, with a focus on understanding the role of the RNA helicase DDX6 and developing new...
- This $160,500 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of mouse models to investigate the role of Caspase-2 in nucleophosmin (NPM1)-mutated acute myeloid leukemia (AML). The project aims to determine the impact of Caspase-2 loss on the self-renewal and myeloproliferative disease progression of NPM1-mutated AML cells. The research is being conducted by the Baylor College of Medicine, a leading private,...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
- This federal Project Grant award of $344,111.00 was provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to Loyola University of Chicago's Health Sciences Campus division. The grant supports research aimed at understanding the fundamental biological mechanisms of myelodysplastic syndromes (MDS), a group of bone marrow failure diseases that can transform into acute myeloid leukemia. The research focuses on targeting "panoptotic pathways" -...
- This federal Project Grant award of $566,998.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research targeting acute myeloid leukemia (AML) using a CD123-directed NK-cell engager and NK cell immune therapy, as well as harnessing the apoptotic machinery through BCL-2 inhibition. The project will be performed by the University of Texas MD Anderson Cancer Center in Houston, TX over a period from September 30, 2024 to...
- This $495,715 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sloan-Kettering Institute for Cancer Research to decipher the pathogenesis and therapeutic vulnerabilities of acute myeloid leukemia (AML) driven by germline RUNX1 mutations. The project aims to develop faithful preclinical models, including genetically engineered mouse models and patient-derived xenografts, to study the genetic events and disease progression from...
- The National Cancer Institute (NCI) awarded a $1,034,176 Project Grant to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) with an award date of August 18, 2025. The grant aims to understand the mechanisms of aberrant RNA splicing and how it drives the development of various hematological malignancies, including myelodysplastic syndrome, chronic lymphocytic leukemia, and acute myeloid leukemia. The research builds on the institution's past...
- This $458,698 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Michigan to identify cellular and molecular mechanisms underlying therapy resistance and disease relapse in acute myeloid leukemia (AML). The project aims to characterize genes and pathways that confer growth advantages to leukemic stem cells, enabling them to persist and regenerate disease after initial clinical remission. This 5-year...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to Case Western Reserve University to conduct research aimed at understanding the fundamental biological mechanisms of acute myeloid leukemia (AML) and developing new therapeutic approaches. The $491,357 award supports investigations into using proteasome inhibitors and an mTORC1 activator molecule to induce metabolic stress and resensitize AML cells to treatment, particularly...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research at the University of Texas MD Anderson Cancer Center to investigate the role of targeting the ATPases BRG1/BRM in the treatment of acute myeloid leukemia (AML). The $542,663 award, provided from April 2025 through March 2030, will fund preclinical studies on the efficacy of two novel targeted agents, FHD-286 and AU15330, to treat AML with MLL rearrangement or mutant NPM1,...